Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008). Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122359919) on January 22, 2026, and is solely responsible for the information contained therein.